MX2017013267A - Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). - Google Patents

Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).

Info

Publication number
MX2017013267A
MX2017013267A MX2017013267A MX2017013267A MX2017013267A MX 2017013267 A MX2017013267 A MX 2017013267A MX 2017013267 A MX2017013267 A MX 2017013267A MX 2017013267 A MX2017013267 A MX 2017013267A MX 2017013267 A MX2017013267 A MX 2017013267A
Authority
MX
Mexico
Prior art keywords
methods
gdf
functionality
inhibitor
increasing strength
Prior art date
Application number
MX2017013267A
Other languages
English (en)
Spanish (es)
Inventor
C Pordy Robert
Qian Xiaobing
donahue Stephen
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017013267A publication Critical patent/MX2017013267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017013267A 2015-04-15 2016-04-15 Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8). MX2017013267A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562147853P 2015-04-15 2015-04-15
US201562234899P 2015-09-30 2015-09-30
US201562261528P 2015-12-01 2015-12-01
PCT/US2016/027774 WO2016168613A1 (en) 2015-04-15 2016-04-15 Methods of increasing strength and functionality with gdf8 inhibitors

Publications (1)

Publication Number Publication Date
MX2017013267A true MX2017013267A (es) 2018-08-15

Family

ID=55809250

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013267A MX2017013267A (es) 2015-04-15 2016-04-15 Metodos para aumentar la fuerza y funcionalidad con inhibidores del factor de diferenciacion y crecimiento 8 (gdf8).

Country Status (14)

Country Link
US (3) US10934349B2 (enExample)
EP (1) EP3283519A1 (enExample)
JP (1) JP6877357B2 (enExample)
KR (2) KR20240128136A (enExample)
CN (1) CN107771081A (enExample)
AU (1) AU2016249015B2 (enExample)
CA (1) CA2982810A1 (enExample)
EA (1) EA201792298A1 (enExample)
HK (1) HK1250236A1 (enExample)
IL (1) IL255010B2 (enExample)
MA (1) MA49661A (enExample)
MX (1) MX2017013267A (enExample)
WO (1) WO2016168613A1 (enExample)
ZA (1) ZA201707550B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
WO2013125667A1 (ja) 2012-02-24 2013-08-29 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG11201500873XA (en) 2012-08-24 2015-04-29 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc region variant
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10307480B2 (en) 2014-11-06 2019-06-04 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
PT3922645T (pt) 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
KR20210082548A (ko) * 2016-06-13 2021-07-05 스칼러 락, 인크. 미오스타틴 억제제의 용도 및 조합 요법
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
LT3773713T (lt) 2018-04-06 2025-08-25 Regeneron Pharmaceuticals, Inc. Leptino receptoriaus agonistinis antikūnas, skirtas kaulų masės didinimui subjektui, kuriam pasireiškia medžiagų apykaitos sutrikimas arba hipoleptinemija
MX2021007394A (es) * 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
CN111303280B (zh) * 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
WO2022092294A1 (ja) 2020-10-30 2022-05-05 学校法人慶應義塾 サルコペニア関連疾患等の新規治療および予防
CN118973613A (zh) 2022-01-25 2024-11-15 早野元词 抑制包括肌肉减少症的与衰老相关的异常的新型治疗与预防
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2026008041A1 (zh) * 2024-07-04 2026-01-08 江苏恒瑞医药股份有限公司 特异性结合潜伏肌生长抑制素的抗原结合分子及其医药用途

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1910220A (en) * 1931-10-21 1933-05-23 Kremser Alois Mechanically operated gate
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
ES2201076T3 (es) 1993-03-19 2004-03-16 The Johns Hopkins University School Of Medicine Factor-8 de diferenciacion del crecimiento.
DE69941116D1 (de) 1998-05-06 2009-08-27 Metamorphix Inc G von gdf-8
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
SK722002A3 (en) 1999-07-20 2003-02-04 Pharmexa As Method for down-regulating GDF-8 activity
US6670140B2 (en) 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
JP5110877B2 (ja) 2003-06-02 2012-12-26 ワイス・エルエルシー 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用
CN1902221A (zh) 2003-12-31 2007-01-24 先灵-普劳有限公司 基于中和表位的生长增强疫苗
US7456149B2 (en) 2004-03-02 2008-11-25 Acceleron Pharma, Inc. ALK7 and myostatin inhibitors and uses thereof
US20070178095A1 (en) 2004-03-23 2007-08-02 Eli Lilly And Company Anti-myostatin antibodies
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
MX2007000976A (es) 2004-08-12 2007-04-10 Wyeth Corp Tratamiento combinado para diabetes, obesidad y enfermedades cardiovasculares utilizando inhibidores del factor 8 de crecimiento y diferenciacion.
NZ538097A (en) 2005-02-07 2006-07-28 Ovita Ltd Method and compositions for improving wound healing
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
BRPI0611069A2 (pt) 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
EP1773041A1 (en) 2005-07-21 2007-04-11 Chao-Hung Wu Audio/video data transmission system using the internet to interconnect telephones
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
ES2533464T3 (es) 2005-10-06 2015-04-10 Eli Lilly And Company Anticuerpos anti-miostatina
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP1968621A2 (en) 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
CA2693378C (en) 2006-08-03 2020-04-14 Myostin Therapeutics Pty Ltd Myostatin antagonists
PL2066695T3 (pl) 2006-09-05 2013-08-30 Lilly Co Eli Przeciwciała przeciwko miostatynie
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
AR069165A1 (es) 2007-11-05 2010-01-06 Novartis Ag Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
AR074777A1 (es) 2008-12-19 2011-02-09 Glaxo Group Ltd Proteinas de union a antigeno
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2993053A1 (en) 2009-04-27 2010-11-04 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
LT2975051T (lt) 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
CA2808382A1 (en) 2010-08-16 2012-02-23 Amgen Inc. Antibodies that bind myostatin, compositions and methods
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
MX2013013445A (es) 2011-05-16 2014-07-28 Genzyme Corp Induccion de tolerancia inmunologica utilizando metotrexato.
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
MY177331A (en) * 2012-06-15 2020-09-12 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
SG11201505960VA (en) 2013-02-01 2015-08-28 Santa Maria Biotherapeutics Inc Administration of an anti-activin-a compound to a subject
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CA2918300A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
US20160075772A1 (en) 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
WO2016168613A1 (en) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
US20180008672A1 (en) 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법

Also Published As

Publication number Publication date
WO2016168613A1 (en) 2016-10-20
KR20240128136A (ko) 2024-08-23
CA2982810A1 (en) 2016-10-20
US20240390489A1 (en) 2024-11-28
EP3283519A1 (en) 2018-02-21
AU2016249015A1 (en) 2017-11-09
US20160304595A1 (en) 2016-10-20
US20210246198A1 (en) 2021-08-12
JP6877357B2 (ja) 2021-05-26
JP2018512435A (ja) 2018-05-17
US12029788B2 (en) 2024-07-09
IL255010B1 (en) 2023-09-01
MA49661A (fr) 2020-06-03
EA201792298A1 (ru) 2018-04-30
CN107771081A (zh) 2018-03-06
ZA201707550B (en) 2018-11-28
HK1250236A1 (zh) 2018-12-07
IL255010A0 (en) 2017-12-31
AU2016249015B2 (en) 2022-03-24
IL255010B2 (en) 2024-01-01
US10934349B2 (en) 2021-03-02
KR20170135967A (ko) 2017-12-08

Similar Documents

Publication Publication Date Title
EA201792298A1 (ru) Способы увеличения силы и функциональности с помощью ингибиторов gdf8
CL2021000717A1 (es) Constructos de anticuerpo para cd70 y cd3. divisional de solicitud 270-2018
CO2018000887A2 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
MX2021009793A (es) Constructos de anticuerpo para dll3 y cd3.
CO2018000882A2 (es) Constructos de anticuerpo para flt3 y cd3
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
MX2022007472A (es) Uso de plinabulina en combinacion con inhibidores de punto de control inmunitario.
EA201792545A1 (ru) Способы и наборы для лечения депрессии
AR088289A1 (es) Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion
EA033403B1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
EA201890390A8 (ru) БИСПЕЦИФИЧЕСКИЕ КОНСТРУКТЫ АНТИТЕЛ, СВЯЗЫВАЮЩИЕ EGFRvIII И CD3
MX2019011657A (es) Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer.
MX2017004344A (es) COMPOSICIONES Y METODOS PARA TRATAR ENFERMEDAD INFLAMATORIA DE INTESTINO USANDO UNA TERAPIA DE COMBINACION DE INHIBIDORES DE MOLECULA PEQUENA DEL RECEPTOR DE QUIMIOCINA C-C TIPO 9 (CCR9) Y ANTICUERPOS BLOQUEADORES ANTI-A4ß7 INTEGRINA.
MX379367B (es) Kit para marcaje radiactivo con galio 68 (68ga) que comprende un inhibidor de metal.
IL287434A (en) Method of treating a child with central precocious puberty using an extended release composition
MX2023007405A (es) Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple.
MX2022000743A (es) Tratamiento mejorado utilizando eyp001.
MX2017009929A (es) Composiciones y métodos para metabolismo muscular mejorado.
BR112017002061A2 (pt) composições e regimes para tratamento bucal
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
MX389143B (es) Metodos de cementacion y composiciones de cemento que contienen lassenite.